Get the Stockscreener App
2.95
0.67%
-0.02
Compass Therapeutics Inc stock is traded at $2.95, with a volume of 815.26K.
It is down -0.67% in the last 24 hours and up +14.34% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$2.97
Open:
$2.9
24h Volume:
815.26K
Relative Volume:
1.00
Market Cap:
$407.93M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-8.4286
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
-7.23%
1M Performance:
+14.34%
6M Performance:
-8.39%
1Y Performance:
+196.16%
1-Day Range:
$2.8001
$2.97
1-Week Range:
$2.8001
$3.3485
52-Week Range:
$0.8741
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.95 | 410.70M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics Inc. stock prediction for this weekVolume Confirmed Setup with Entry Confidence - Newser
Momentum divergence signals in Compass Therapeutics Inc. chartFree Fast Gaining Stock Screener Report - Newser
When is the best time to exit Compass Therapeutics Inc.Weekly Growth Portfolio Performance Summary - Newser
Price action breakdown for Compass Therapeutics Inc.Weekly Return Plan for Conservative Traders - Newser
What makes Compass Therapeutics Inc. stock price move sharplyMarket Downturn Defense Strategy Analysis - Newser
Using data tools to time your Compass Therapeutics Inc. exitStrong Buy Signal Summary with Entry Zone - Newser
How volatile is Compass Therapeutics Inc. stock compared to the marketBreakout Stocks Strategy With Low Risk - jammulinksnews.com
What are Compass Therapeutics Inc. company’s key revenue driversAI Powered Target Finder For Consistent Profits - jammulinksnews.com
Can machine learning forecast Compass Therapeutics Inc. recoveryFree Low Volatility Stable Growth Picks - Newser
Is Compass Therapeutics Inc. stock a growth or value playLong-Term Safety Investment Analysis Report - Newser
Technical signs of recovery in Compass Therapeutics Inc.Bear Market Safe Zone Technical Analysis - Newser
What analysts say about Compass Therapeutics Inc. stock outlookFree AI-Powered Trade Planning with Indicators - Newser
What does recent volatility data suggest for Compass Therapeutics Inc.Low Drawdown Stock Screener with Analysis - Newser
Why Compass Therapeutics Inc. stock attracts strong analyst attentionSummary of Trade Cycles in 5-Year Range - Newser
Compass Therapeutics Inc. Rebound Backed by Sentiment ShiftAlpha Driven Watchlist With Alerts Published - metal.it
Has Compass Therapeutics Inc. formed a bullish divergenceInvestment Timing Strategy with Market Filters - Newser
Can Compass Therapeutics Inc. Escape Recent Bear ChannelLow Risk High Return Opportunities Identified - metal.it
Published on: 2025-07-29 20:25:47 - metal.it
Is Compass Therapeutics Inc. a candidate for recovery playShort Term Opportunity Finder with Tools - Newser
Compass Therapeutics Inc. Rebounds From Oversold Zone — Now WhatEarly Breakout Entry Point Notifications Sent - metal.it
What is Compass Therapeutics Inc. company’s growth strategyFree Stock Trend Scanner For 2025 - jammulinksnews.com
Is Compass Therapeutics Inc. stock overvalued or undervaluedFree Capital Allocation Plans - jammulinksnews.com
New York State Common Retirement Fund Has $58,000 Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
How strong is Compass Therapeutics Inc. company’s balance sheetMaximize returns with strategic trading plans - jammulinksnews.com
What are the latest earnings results for Compass Therapeutics Inc.Build a portfolio for long-term financial success - jammulinksnews.com
Why is Compass Therapeutics Inc. stock attracting strong analyst attentionBreakthrough stock performance - jammulinksnews.com
How does Compass Therapeutics Inc. generate profit in a changing economyRapid return acceleration - jammulinksnews.com
Is it the right time to buy Compass Therapeutics Inc. stockExceptional gains - jammulinksnews.com
What is the dividend policy of Compass Therapeutics Inc. stockTremendous wealth creation - jammulinksnews.com
What institutional investors are buying Compass Therapeutics Inc. stockBuild a strong portfolio for growth and safety - jammulinksnews.com
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Therapeutics Inc Stock (CMPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):